Peptide dosing chart: every compound, by category

This page links every compound we cover, grouped by what people use it for. Each line shows a typical protocol from that compound's dosing page, with the origin of the number: a regulator's label, a clinical trial, a competitor guide, a vendor guide, or community reports. We do not add numbers here that are not on the compound's own page.

Read every number as what that source reported, not as advice. Doses for research peptides mostly come from guides and forums, because human trials either do not exist or used different products.

To turn a dose into syringe units, use the reconstitution calculator. For the math behind it, see mg to units conversion.

5-Amino-1MQ (subcutaneous)

• Subcutaneous, guide default (competitor guides): 2.5 to 5 mg, 2.5 mg daily on days 1 and 2, then 5 mg daily (or 2.5 mg twice daily). Competitor guide.
• Subcutaneous, common start (community): 2.5 to 5 mg, once daily, often 5 days on and 2 off. Community-reported.
• Subcutaneous, high dose (community): 10 to 50 mg, once daily at 10, 25 or 50 mg. Community-reported.

AOD-9604 (subcutaneous)

• Fat loss, most common start (dosing guides and community): 250 to 300 mcg, once daily. Community-reported.
• Fat loss, 300 to 500 mcg ramp (dosing guides): 300 to 500 mcg, once daily; 300 mcg for weeks 1 to 4, then 500 mcg to week 12. Competitor guide.
• Fat loss, weight-tiered, under 150 lb (dosing guide): 250 to 400 mcg, once daily. Competitor guide.

Cagrilintide (subcutaneous)

• Weight loss, phase 2 monotherapy dose-finding (clinical trial): 0.3 to 4.5 mg, once weekly at 0.3, 0.6, 1.2, 2.4 or 4.5 mg depending on arm. Clinical study.
• Weight loss, phase 2 4.5 mg arm escalation (as described by dosing guides): 0.6 to 4.5 mg, once weekly, 2 weeks per step, then hold 4.5 mg. Competitor guide.
• Low-dose add-on to retatrutide or tirzepatide (community): 0.1 to 0.5 mg, once weekly. Community-reported.

MOTS-c (subcutaneous)

• Standard intermittent: 5 mg, 2 to 3 times a week. Competitor guide.
• Higher tier: 10 mg, 2 to 3 times a week. Competitor guide.
• Monthly weekly block: 10 mg, once a week for 4 weeks. Community-reported.

Retatrutide (subcutaneous)

• Weight loss, phase 3 trial schedule (TRIUMPH): 2 to 12 mg, once weekly. Start at 2 mg, step up every 4 weeks to a target of 4, 9 or 12 mg, then hold. Clinical study.
• Weight loss, phase 3 step ladder as published by dosing guides: 2 to 12 mg, once weekly, 4 weeks at each step: 2, 4, 6, 9, then 12 mg and hold. Competitor guide.
• Weight loss, common community start: 0.25 to 1 mg, once weekly, held a few weeks to judge tolerance before stepping up. Community-reported.

Semaglutide (subcutaneous)

• Type 2 diabetes, FDA label titration (Ozempic injection): 0.25 to 2 mg, once weekly, same day each week; at least 4 weeks per step, then hold at 0.5, 1 or 2 mg (2 mg max). Regulatory.
• Weight loss, compounded or research vial, Wegovy-style ladder (guide protocol): 0.25 to 2.4 mg, once weekly; 4 weeks per step, then hold at 2.4 mg. Competitor guide.
• Weight loss, common community compounded range: 0.25 to 2.5 mg, once weekly, ongoing. Community-reported.

Tirzepatide (subcutaneous)

• Type 2 diabetes, FDA label titration (Mounjaro): 2.5 to 15 mg, once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose. Regulatory.
• Weight loss, compounded label-mirror titration (guide protocol): 2.5 to 15 mg, once weekly. Up 2.5 mg every 4 weeks, then hold the dose that works. Competitor guide.
• Extended dose steps with research vials (vendor guide describing users): 2.5 mg, once weekly, staying longer than 4 weeks at each dose. Vendor guide.

BPC-157 (subcutaneous)

• Starter: 250 mcg, once daily. Competitor guide.
• Standard (most cited): 250 mcg, twice daily, about 12 hours apart (500 mcg a day). Competitor guide.
• Forum standard near the injury: 250 to 500 mcg, once daily. Community-reported.

BPC-157 + TB-500 blend (subcutaneous)

• Conservative (premixed blend): 500 mcg (blend total), once daily (250 mcg of each peptide). Competitor guide.
• Standard (premixed blend, most common): 1,000 mcg (blend total), once daily (500 mcg of each peptide). Competitor guide.
• Acute injury (premixed blend): 1,500 mcg (blend total), once daily (750 mcg of each peptide). Competitor guide.

GHK-Cu (subcutaneous)

• Titration: 1 to 2 mg, once daily, 5 days a week. Competitor guide.
• Three times a week: 2 mg, Monday, Wednesday and Friday. Competitor guide.
• Starter: 1 mg, 5 to 7 nights a week. Competitor guide.

GLOW (subcutaneous)

• Consensus daily dose: 2.33 mg (blend total), once daily: 10 units of a 70 mg vial in 3 mL. Competitor guide.
• Starter tier: 1.17 mg (blend total), once daily, days 1 to 7 (5 units at 3 mL). Competitor guide.
• Forum post-surgery report: 3.5 to 7 mg (blend total), daily, later 3 days a week. Community-reported.

KLOW (subcutaneous)

• Titration ladder: 2 to 6 mg (blend total), once daily (7.5, 15, 22.5 then 15 units at 3 mL). Competitor guide.
• Starter tier: 2 mg (blend total), once daily at a fixed hour, days 1 to 14 (4 mL dilution). Competitor guide.
• Standard tier: 4 mg (blend total), once daily at a fixed hour (4 mL dilution). Competitor guide.

KPV (subcutaneous)

• Titration: 200 to 500 mcg, once daily, stepping up weekly. Competitor guide.
• Conservative: 250 mcg, once daily. Competitor guide.
• Standard: 500 mcg, once daily. Competitor guide.

TB-500 (subcutaneous)

• Loading phase (standard): 2 to 2.5 mg, twice weekly (4 to 5 mg a week). Competitor guide.
• Maintenance phase: 2 to 2.5 mg, once weekly. Competitor guide.
• Forum high loading: 5 mg, 5 mg shots, about 10 mg a week (some go to 20 mg) for 4 to 6 weeks, then 5 mg weekly. Community-reported.

CJC-1295 (subcutaneous)

• With DAC: forum convention: 1 to 2 mg, 1 to 2 mg a week, split into 1 or 2 injections. Community-reported.
• With DAC: self-logged doses: 0.4 to 0.6 mg, per logged entry; median bucket 0.4 to 0.6 mg. Community-reported.
• With DAC: whole 2 mg vial weekly: 2 mg, once a week, same day each week. Competitor guide.

CJC-1295 (no DAC) + Ipamorelin (subcutaneous)

• Classic bedtime shot (amount is per peptide): 100 mcg, once daily, before bed. Competitor guide.
• Forum convention (CJC amount; ipamorelin paired): 100 to 200 mcg, 1 to 2 times daily, often after strength training. Community-reported.
• Stack guide range (amount is per peptide): 100 to 200 mcg, 1 to 3 times daily, fasted. Competitor guide.

GHRP-2 and GHRP-6 (subcutaneous)

• GHRP-2: forum convention: 100 to 150 mcg, 2 to 3 times daily, fasted. Community-reported.
• Standard shot (either peptide): 100 mcg, 1 to 3 times daily; the bedtime shot matters most. Competitor guide.
• Clinic regimen: GHRP-2 plus GHRP-6 plus sermorelin (each): 100 mcg, 3 times daily, GHRP-2 and GHRP-6 at 100 mcg each with sermorelin. Clinical study.

IGF-1 LR3 (subcutaneous)

• Forum convention: 20 to 40 mcg, once daily, after training. Community-reported.
• With a meal: 20 to 40 mcg, once daily. Competitor guide.
• Beginner: 20 to 30 mcg, daily. Competitor guide.

Ipamorelin (subcutaneous)

• Beginner: 100 to 200 mcg, once daily, before bed. Competitor guide.
• Beginner ramp: 100 to 200 mcg, once daily. Competitor guide.
• Forum convention: 200 to 300 mcg, 2 to 3 times daily. Community-reported.

Sermorelin (subcutaneous)

• Forum convention: 200 to 300 mcg, once daily at bedtime. Community-reported.
• Standard nightly: 200 to 300 mcg, once nightly. Competitor guide.
• Clinic regimen with GHRP-2 and GHRP-6: 100 mcg, 3 times daily, combined with GHRP-2 and GHRP-6. Clinical study.

Tesamorelin (subcutaneous)

• Egrifta SV label dose: 1.4 mg, once daily. Regulatory.
• Forum convention: 2 mg, once daily. Community-reported.
• Tolerance-check start: 1 to 2 mg, once daily. Competitor guide.

Epitalon (subcutaneous)

• Standard 20-day course (community convention): 5 mg, once daily in the evening. Competitor guide.
• Telehealth clinic course: 5 to 10 mg, once daily. Vendor guide.
• Sleep, microgram range (community): 100 to 500 mcg, once daily, usually at bedtime. Community-reported.

NAD+ (subcutaneous)

• Starter (subQ): 25 mg, twice a week. Competitor guide.
• Standard (subQ, where most home plans land): 50 mg, 3 times a week. Competitor guide.
• Starter (subQ, community): 25 to 50 mg, twice a week. Community-reported.

SS-31 (subcutaneous)

• Barth syndrome (FDA label): 40 mg, once daily. Regulatory.
• Microdose: 100 to 500 mcg, once daily. Community-reported.
• Low tier: 2 to 5 mg, once daily. Competitor guide.

Adamax (subcutaneous)

• Focus, 8-week subcutaneous ladder (competitor guide): 300 to 1,000 mcg, once daily, stepping up every 2 weeks. Competitor guide.
• Extended subcutaneous ladder with equal time off (competitor guide): 300 to 1,000 mcg, once daily, stepping up every 2 weeks, then hold at 1000 mcg. Competitor guide.
• Most common self-reported subcutaneous dose (community): 0.2 to 0.4 mg, once daily. Community-reported.

Selank (subcutaneous)

• Subcutaneous, once daily (guide): 250 to 500 mcg, once daily. Competitor guide.
• Subcutaneous (guide): 200 to 500 mcg, once daily. Competitor guide.
• Situational subcutaneous (community): 250 to 333 mcg, as needed, before events or in the evening for sleep. Community-reported.

Semax (subcutaneous)

• Subcutaneous planning dose (guide): 500 mcg, once daily. Competitor guide.
• Neuroprotection, subcutaneous (guide): 100 to 200 mcg, daily. Competitor guide.
• Daily subcutaneous (community): 500 to 1,000 mcg, once daily, in the morning. Community-reported.

PT-141 (subcutaneous)

• Low sexual desire in women, Vyleesi label dose: 1.75 mg, as needed. No more than 1 dose in 24 hours; more than 8 doses a month is not recommended. Regulatory.
• Women, label dose from a vial (guides): 1.75 mg, as needed. No more than 1 dose in 24 hours; more than 8 doses a month is not recommended. Competitor guide.
• Men and couples, community use: 1 to 3 mg, on demand. Some users cap it at twice a week. Community-reported.

DSIP (subcutaneous)

• Sleep, beginner tier (guide): 100 mcg, once nightly. Competitor guide.
• Sleep, standard tier (guide): 200 mcg, once nightly. Competitor guide.
• Sleep, community standard: 100 to 200 mcg, once nightly. Community-reported.